BRPI0411519A - membrana viral reconstituìda, método para produzir uma membrana viral reconstituìda, e, composição farmacêutica - Google Patents

membrana viral reconstituìda, método para produzir uma membrana viral reconstituìda, e, composição farmacêutica

Info

Publication number
BRPI0411519A
BRPI0411519A BRPI0411519-8A BRPI0411519A BRPI0411519A BR PI0411519 A BRPI0411519 A BR PI0411519A BR PI0411519 A BRPI0411519 A BR PI0411519A BR PI0411519 A BRPI0411519 A BR PI0411519A
Authority
BR
Brazil
Prior art keywords
membrane
reconstituted
viral membrane
reconstituted viral
producing
Prior art date
Application number
BRPI0411519-8A
Other languages
English (en)
Inventor
Antonius Johannes Hen Stegmann
Jan Christiaan Wilschut
Johannes Henricus Gerar Berkum
Original Assignee
Bestewil Holding Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bestewil Holding Bv filed Critical Bestewil Holding Bv
Publication of BRPI0411519A publication Critical patent/BRPI0411519A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

"MEMBRANA VIRAL RECONSTITUìDA, MéTODO PARA PRODUZIR UMA MEMBRANA VIPAL RECONSTITUìDA, E, COMPOSIçãO FARMACêUTICA". A presente invenção refere-se a vacinas direcionadas contra antígenos, tais como proteínas de membrana de patógenos ou células tumorais. A invenção refere-se ainda a métodos de formar membranas virais reconstituídas, com atividade de fusão de membrana, que são membranas de bicamadas lipídicas, preferivelmente contendo lipídeos naturais de um vírus, uma proteína de fusão viral, um ou mais antígenos adicionais opcionais, bem como adjuvantes anfifílicos. As composições farmacêuticas compreendendo tais membranas virais reconstituídas são também parte da invenção.
BRPI0411519-8A 2003-06-19 2004-06-18 membrana viral reconstituìda, método para produzir uma membrana viral reconstituìda, e, composição farmacêutica BRPI0411519A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL0300450 2003-06-19
PCT/NL2004/000437 WO2004110486A1 (en) 2003-06-19 2004-06-18 Functionally reconstituted viral membranes containing adjuvant

Publications (1)

Publication Number Publication Date
BRPI0411519A true BRPI0411519A (pt) 2006-08-01

Family

ID=33550371

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411519-8A BRPI0411519A (pt) 2003-06-19 2004-06-18 membrana viral reconstituìda, método para produzir uma membrana viral reconstituìda, e, composição farmacêutica

Country Status (20)

Country Link
US (1) US7618641B2 (pt)
EP (2) EP2368576B1 (pt)
JP (1) JP4685005B2 (pt)
KR (1) KR101225199B1 (pt)
CN (1) CN100556454C (pt)
AR (1) AR056245A1 (pt)
AU (1) AU2004246974B2 (pt)
BR (1) BRPI0411519A (pt)
CA (1) CA2527735C (pt)
DK (2) DK1633395T3 (pt)
ES (2) ES2390454T3 (pt)
IL (1) IL172584A (pt)
MX (1) MXPA05013929A (pt)
NO (1) NO20055934L (pt)
PL (2) PL2368576T3 (pt)
RU (1) RU2348428C2 (pt)
TW (1) TWI329130B (pt)
UA (1) UA87269C2 (pt)
WO (1) WO2004110486A1 (pt)
ZA (1) ZA200509907B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1841860A2 (en) 2005-01-18 2007-10-10 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Mycobacteria with mannose cap-deficient lipoarabinomannan
TWI397419B (zh) * 2006-03-22 2013-06-01 Abbott Biologicals Bv 病毒顆粒的鼻內或吸入給藥
US8535683B2 (en) 2006-03-22 2013-09-17 Abbott Biologicals B.V. Intranasal or inhalational administration of virosomes
AR059972A1 (es) * 2006-03-22 2008-05-14 Solvay Pharm Bv Administracion intranasal o inhalacional de virosomas
US8916164B2 (en) * 2007-08-29 2014-12-23 Abivax Methods of enhancing adjuvaticity of vaccine compositions
EP2058002A1 (en) 2007-10-31 2009-05-13 Bestewil Holding B.V. Reconstituted respiratory syncytial virus membranes and use as respiratory syncytial virus vaccine
MX2011007703A (es) 2009-02-06 2011-09-28 Mymetics Corp Antigenos gp41 novedosos.
CN102365095B (zh) 2009-02-06 2015-11-25 麦米提斯公司 分裂gp41
EA031379B1 (ru) * 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
WO2011128720A1 (en) 2010-04-14 2011-10-20 Mymetics Corporation Trans-activator of transcription protein
US9295720B2 (en) 2010-08-27 2016-03-29 Pantarhei Bioscience B.V. Immunotherapeutic method for treating prostate cancer
JP2013542928A (ja) * 2010-09-30 2013-11-28 フランバックス ソチエタ レスポンサビリタ リミテ ビロソーム粒子の生成
RU2441667C1 (ru) * 2010-12-09 2012-02-10 Иосиф Григорьевич Атабеков Новый тип частиц-носителей (платформ) для получения активных комплексов
RU2440140C1 (ru) * 2010-12-09 2012-01-20 Иосиф Григорьевич Атабеков Иммуногенная композиция, содержащая чужеродные антигены на поверхности сферических носителей, полученных при термической денатурации спиральных вирусов
WO2015000831A1 (en) * 2013-07-02 2015-01-08 Crucell Holland B.V. Method for preparing virosomes
WO2016039619A1 (en) 2014-09-12 2016-03-17 Bestewil Holding B.V. Methods for providing adjuvanted virosomes and adjuvanted virosomes obtainable thereby
WO2016039620A2 (en) 2014-09-12 2016-03-17 Bestewil Holding B.V. Respiratory syncytial virus virosomes
WO2016080830A2 (en) 2014-11-18 2016-05-26 Pantarhei Bioscience B.V. Immunotherapeutic method for treating pancreatic cancer
CN111511392A (zh) 2017-10-31 2020-08-07 潘塔希生物科学股份有限公司 用于治疗和/或预防肺癌的免疫治疗方法
WO2020048924A1 (en) 2018-09-03 2020-03-12 Laboratoire Hra-Pharma Zp3 fragments in immunotherapy of ovarian cancer
US11523988B2 (en) 2018-11-29 2022-12-13 Catalent U.K. Swindon Zydis Limited Oral dispersible vaccine comprising virosomes
WO2020121062A1 (en) 2018-12-12 2020-06-18 Anergis S.A. Methods of improving efficacy of allergy vaccines
WO2021207303A1 (en) * 2020-04-07 2021-10-14 Alsatech, Inc. Immune stimulation against coronavirus infections
US20250026818A1 (en) 2021-10-19 2025-01-23 Sciencemed Spóka z ograniczon odpowiedzialnoci Male contraception
WO2023237726A1 (en) 2022-06-10 2023-12-14 Pantarhei Oncology B.V. An intracellular tumor-specific variant of human zona pellucida glycoprotein 3 and nucleic acids coding therefor for use in the treatment of cancer
CN120076824A (zh) * 2022-10-25 2025-05-30 宁波明亦生物科技有限公司 质膜透化灭活口服疫苗

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4542212A (en) * 1975-10-14 1985-09-17 Institut Pasteur Phosphorylated 3-glyceryl-esters of glucose
JPS5929931B2 (ja) * 1980-12-09 1984-07-24 オムロン株式会社 安全スイツチ
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
JPH0688911B2 (ja) 1985-06-06 1994-11-09 国立予防衛生研究所長 インフルエンザワクチン及びその製造方法
ATE71303T1 (de) 1986-01-14 1992-01-15 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
NZ224422A (en) 1987-05-05 1990-11-27 Molecular Eng Ass Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid
NZ240369A (en) 1990-10-30 1993-09-27 Daiichi Seiyaku Co Muramyl dipeptide derivatives and vaccine compositions
US20030113347A1 (en) * 1991-05-08 2003-06-19 Schweiz. Serum- & Impfinstitut Bern Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
CA2086831C (en) 1991-05-08 1999-03-16 Reinhard Gluck Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
US5879685A (en) * 1991-05-08 1999-03-09 Schweiz, Serum- & Impfinstitut Bern Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
WO1997038010A2 (en) * 1996-04-11 1997-10-16 The University Of British Columbia Fusogenic liposomes
CA2400468C (en) 2000-02-15 2012-12-18 Intellivax International Inc. Proteosome influenza vaccine
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
US20030092145A1 (en) * 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
AU2003296592A1 (en) * 2002-11-20 2004-06-15 Crucell Holland B.V. Antigen-complexes
US7491395B2 (en) * 2002-11-20 2009-02-17 Bestewil Holding B.V. Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination

Also Published As

Publication number Publication date
EP2368576A2 (en) 2011-09-28
AU2004246974B2 (en) 2010-05-06
EP1633395A1 (en) 2006-03-15
ES2536689T3 (es) 2015-05-27
CA2527735C (en) 2014-12-16
EP2368576A3 (en) 2012-03-28
AU2004246974A1 (en) 2004-12-23
UA87269C2 (ru) 2009-07-10
ZA200509907B (en) 2006-11-29
CA2527735A1 (en) 2004-12-23
AR056245A1 (es) 2007-10-03
DK1633395T3 (da) 2012-10-29
IL172584A0 (en) 2006-04-10
MXPA05013929A (es) 2006-03-08
CN100556454C (zh) 2009-11-04
CN1805754A (zh) 2006-07-19
TWI329130B (en) 2010-08-21
IL172584A (en) 2010-11-30
PL1633395T3 (pl) 2012-12-31
PL2368576T3 (pl) 2015-12-31
JP4685005B2 (ja) 2011-05-18
KR20060030047A (ko) 2006-04-07
RU2348428C2 (ru) 2009-03-10
EP1633395B1 (en) 2012-08-01
JP2006527598A (ja) 2006-12-07
EP2368576B1 (en) 2015-02-25
RU2006101394A (ru) 2006-06-10
US20060193873A1 (en) 2006-08-31
KR101225199B1 (ko) 2013-01-23
TW200510538A (en) 2005-03-16
NO20055934L (no) 2006-03-20
WO2004110486A1 (en) 2004-12-23
US7618641B2 (en) 2009-11-17
ES2390454T3 (es) 2012-11-13
DK2368576T3 (en) 2015-05-18

Similar Documents

Publication Publication Date Title
BRPI0411519A (pt) membrana viral reconstituìda, método para produzir uma membrana viral reconstituìda, e, composição farmacêutica
Li et al. Enhancing the immunogenicity of lipid-nanoparticle mRNA vaccines by adjuvanting the ionizable lipid and the mRNA
JP7514206B2 (ja) コロナウイルスワクチン
EP4226938A2 (en) Coronavirus vaccine
BRPI0518818A2 (pt) sistema de distribuiÇço de proteÍna
CN107810009A (zh) 涉及施用至少一种mRNA构建体的初免‑加强方案
BR0214386A (pt) Método para identificação de enzimas de objetivação a tumor
BRPI0314373B8 (pt) produto imunogênico estável para a indução de anticorpos contra uma ou várias proteínas antigênicas em um indivíduo, composições farmacêutica, imunogênica e de vacina e processo de preparação de um produto imunogênico
WO2023147092A9 (en) Coronavirus vaccine
US12208136B2 (en) Coronavirus vaccine
AU2023317822A1 (en) Rna for preventing or treating tuberculosis
CN117157400A (zh) 用于编码核酸的治疗潜力的效力测定
US20240383947A1 (en) Virus vaccine
WO2024216214A1 (en) Rna for preventing or treating tuberculosis
CN116650633A (zh) 冠状病毒疫苗
CN121002196A (zh) 用于多种编码核酸的接头序列效力测定
CN120712350A (zh) 用于药物用途的rna制剂
AR042237A1 (es) Obtencion de estructuras cocleares, composiciones vacunales, adyuvantes y sus intermediarios
HK40102659A (zh) 病毒疫苗
HK40061483A (en) Coronavirus vaccine
HK40098889A (en) Coronavirus vaccine
TH72411A (th) เมมเบรนไวรัสที่ประกอบขึ้นใหม่เชิงหน้าที่ที่มีสารเสริม

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements